Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Average Recommendation of "Reduce" from Analysts

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) have received a consensus recommendation of "Reduce" from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $18.63.

Several equities research analysts have commented on the company. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Wells Fargo & Company lowered their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. JMP Securities cut their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th.

Integra LifeSciences Price Performance

NASDAQ IART opened at $13.55 on Tuesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -150.54, a PEG ratio of 0.73 and a beta of 1.27. The business has a 50 day simple moving average of $17.82 and a 200 day simple moving average of $21.66. Integra LifeSciences has a 52-week low of $11.60 and a 52-week high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. During the same quarter last year, the company earned $0.55 EPS. The firm's quarterly revenue was up 3.7% compared to the same quarter last year. Analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its stake in shares of Integra LifeSciences by 10.4% during the 1st quarter. Wellington Management Group LLP now owns 2,766,125 shares of the life sciences company's stock worth $60,827,000 after buying an additional 259,987 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Integra LifeSciences by 5.0% in the 1st quarter. Alliancebernstein L.P. now owns 2,706,434 shares of the life sciences company's stock valued at $59,514,000 after buying an additional 128,041 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Integra LifeSciences by 2,418.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock valued at $39,581,000 after buying an additional 1,728,480 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Integra LifeSciences by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company's stock worth $36,515,000 after buying an additional 35,790 shares during the period. Finally, Paradigm Capital Management Inc. NY lifted its holdings in shares of Integra LifeSciences by 170.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock worth $32,457,000 after buying an additional 901,600 shares in the last quarter. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.